PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC13231543::ACT047748

sP10

Evidence text

Paper-level observation

WB analysis demonstrated accelerated NPM1 degradation (shorter half-life) in sP10-treated cells (Fig. 5C).
figureConfidence: medium

Assay observation

Activity
Anticancer
Subtype
Not reported by source
Measure
qualitative
Comparator
=
Raw observation
accelerated NPM1 degradation (shorter half-life)
Normalized measurement
=0
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
SK-Hep1
Assay method
Not reported by source
Sequence
YGRKKRRQRRRCGPVWFLIFSYFLFFSISLARGPC
Standardization
ready simple

Source publication

Peptide aptamer sP10 targeting NPM1 attenuates liver fibrosis and hepatocellular carcinoma.

Journal of Translational Medicine · 2026

DOI 10.1186/s12967-026-08144-8 PMC13231543
Parent mention

Related peptide identities

PEPDIA-PLP-003251

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.